A Phase 1, Open-Label, Dose-Escalation, Dose-Expansion, Safety and Tolerability Study of Pemigatinib in Japanese Subjects With Advanced Malignancies - (FIGHT-102)
Latest Information Update: 15 Nov 2022
At a glance
- Drugs Pemigatinib (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Acronyms FIGHT-102
- Sponsors Incyte Corporation
- 01 Apr 2022 Results of population pharmacokinetics model from three trials (phase 1 dose-escalation/dose-expansion study, a phase 1 Japanese PK bridging study, and a phase 2 cholangiocarcinoma study.) published in the Clinical Pharmacology in Drug Development
- 15 Apr 2020 Status changed from recruiting to completed.
- 04 Dec 2019 Planned End Date changed from 1 Dec 2019 to 13 Oct 2020.